Professor S Lovestone
University of Oxford
WNT signaling: biomarker and target evaluation in Alzheimer's disease
The consistent failure of biopharmaceutical pipelines to modify Alzheimer’s disease progression indicates a need for new and creative solutions. In this project we will explore elements of the canonical (WNT/GSK3) and non-canonical (WNT/JNK) signaling pathways as novel targets that could be used to monitor and modify Alzheimer’s progression. Our teams are applying a multidisciplinary approach that combines brain-oriented drug screening, new genetic and pharmacological tools, new animal models and human blood and cerebrospinal fluid samples, which, together, explore the impact on AD of novel WNT elements, including but not limited to the apolipoprotein clusterin, the WNT inhibitor DKK1 and the transcription factor Nrf2.